Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Bernstein SocGen on UnitedHealth Group (UNH): 'Expecting a strong 2Q driven by MA and potential for guidance raise'
• Akari Therapeutics closes $5.5M PIPE, raises $8.3M total in Q2 2026
• Jefferies Assumes Radico Khaitan Ltd (RDCK:IN) at Buy